greeksoup/ stock research
Stock research / United States / NRIX / Filings

Nurix Therapeutics, Inc. SEC filings

Nurix Therapeutics filed 19 documents with the SEC in the last twelve months, the latest report being the 10-Q of 13 October 2026.

Filings in twelve months1911 of them 8-K news
Latest report10-Qfiled 13 Oct 2026
Latest filing10-Q13 Oct 2026
Last results, two-day move+6.9%results filed 13 Oct 2026
New to this? How to read this page
  1. Companies file with the SEC when something happens. 10-Q and 10-K are the quarterly and annual reports; 8-K is news that cannot wait for the next report.
  2. An 8-K says which items it covers, such as results, a change at the top or a big contract. A foreign company files a 6-K instead.
  3. The results release is usually an 8-K filed the day results come out, before the 10-Q or 10-K.
  4. Every filing links to the original on EDGAR, the SEC's own site.

Twelve months of filings

by kind

Most of the filings were other company news (7). Results came out 4 times.

Each mark is one filing on the day it was filed, in rows by kind. Hover or tap a mark for the form and what it was about.

The share price around each results release

close before to close after

Over the last 4 releases the share price moved 5.5% on average in the two days around results, the most on 28 Jan 2026 (-9.4%).

28 Jan 2026-9.4%$19.41 to $17.59
8 Apr 2026-0.7%$16.35 to $16.24
9 Jul 2026-5.1%$24.31 to $23.06
13 Oct 2026+6.9%$22.14 to $23.67
Daily closeResults filed

Each ring marks a results filing. The move runs from the last close before the filing to the first close after it, so it covers results released before the open or after the close. Hover the line for any day's close.

What the company told investors on 8-K

11 filings

Nurix Therapeutics's 11 news filings (8-K) were mostly about results of operations (4) and regulation FD disclosure (4).

  • Results of operationsThe quarterly results release
    4 · latest 13 Oct 2026
  • Regulation FD disclosureMaterial shared with investors, often slides or a presentation
    4 · latest 11 Jun 2026
  • Other eventsNews the company chose to file
    3 · latest 11 Jun 2026
  • Material agreementA large contract or deal was signed
    1 · latest 8 Jun 2026
  • Shareholder voteResults of a vote at a shareholder meeting
    1 · latest 15 May 2026
  • Officer or director changeSomeone joined, left or changed role at the top
    1 · latest 10 Nov 2025

Each line is one kind of news, with what it means in plain words. Each square is one filing; a filing can carry more than one kind, so the squares can add up to more than the filings. The date opens the latest one on EDGAR.

How it compares

every company on the site

    The bar ranks every company on the site from the lowest on the left to the highest on the right, in three equal thirds; the small figures under it are the values where each third starts, and the black tick is the middle company. The orange dot is this company; the grey ticks are the other companies in its industry (hover or tap for names). A hatched block is companies tied at none.

    Every filing as a table

    In the last twelve months Nurix Therapeutics, Inc. filed 19 documents with the SEC of the kinds listed here: 11 current reports (8-K), about 4 results of operations; 4 regulation FD disclosure; 3 other events; 1 material agreement; 1 shareholder vote; 3 quarterly reports (10-Q), 1 annual report to shareholders (ARS), 1 additional proxy material (DEFA14A), 1 proxy statement (DEF 14A), 1 employee share plan registration (S-8), 1 annual report (10-K). The latest, filed 13 October 2026: 10-Q, quarterly report. The 10-K, the 10-Qs and the proxy statement themselves, each with a link to open it, are on the documents page.

    FiledFormWhat it was aboutPeriod or event dateFiling
    13 October 202610-Qquarterly report31 August 2026EDGAR
    13 October 20268-KResults of operations12 October 2026EDGAR
    9 July 202610-Qquarterly report31 May 2026EDGAR
    9 July 20268-KResults of operations9 July 2026EDGAR
    11 June 20268-KRegulation FD disclosure, Other events11 June 2026EDGAR
    8 June 20268-KMaterial agreement, Regulation FD disclosure6 June 2026EDGAR
    15 May 20268-KShareholder vote15 May 2026EDGAR
    8 April 202610-Qquarterly report28 February 2026EDGAR
    8 April 20268-KResults of operations8 April 2026EDGAR
    27 March 2026ARSannual report to shareholders30 November 2025EDGAR
    27 March 2026DEFA14Aadditional proxy materialEDGAR
    27 March 2026DEF 14Aproxy statement15 May 2026EDGAR
    6 March 20268-KOther events6 March 2026EDGAR
    28 January 2026S-8employee share plan registrationEDGAR
    28 January 202610-Kannual report30 November 2025EDGAR
    28 January 20268-KResults of operations28 January 2026EDGAR
    12 January 20268-KRegulation FD disclosure12 January 2026EDGAR
    9 December 20258-KRegulation FD disclosure, Other events6 December 2025EDGAR
    10 November 20258-KOfficer or director change6 November 2025EDGAR
    An 8-K is what a company files within four business days of a material event; the SEC numbers the events, and the words here are the SEC's own headings, shortened.
    Read moreForm 4, Form 144, 13F and Schedule 13D and 13G have their own pages. Prospectus supplements and correspondence are not listed.